See more : Assurant, Inc. 5.25% Subordinat (AIZN) Income Statement Analysis – Financial Results
Complete financial analysis of Hemogenyx Pharmaceuticals Plc (HOPHF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Hemogenyx Pharmaceuticals Plc, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Flughafen Zürich AG (FLGZY) Income Statement Analysis – Financial Results
- Viva China Holdings Limited (8032.HK) Income Statement Analysis – Financial Results
- Xstate Resources Limited (XST.AX) Income Statement Analysis – Financial Results
- CapStar Financial Holdings, Inc. (CSTR) Income Statement Analysis – Financial Results
- MoneyMe Limited (MME.AX) Income Statement Analysis – Financial Results
Hemogenyx Pharmaceuticals Plc (HOPHF)
About Hemogenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML), subset of acute lymphoblastic leukaemia, and myelodysplastic syndrome conditioning bone marrow transplants to substitute traditional chemotherapy and/or radiation; HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants. The company was founded in 2012 and is headquartered in London, the United Kingdom.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.85K | 0.00 |
| Cost of Revenue | 645.68K | 2.60M | 283.65K | 350.72K | 421.82K | 348.27K | 100.48K | 66.86K | 0.00 | 0.00 |
| Gross Profit | -645.68K | -2.60M | -283.65K | -350.72K | -421.82K | -348.27K | -100.48K | -66.86K | 6.85K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% |
| Research & Development | 90.63K | 487.10 | 50.82 | 114.41 | 28.14 | 73.50 | 18.96 | 2.00 | 0.00 | 0.00 |
| General & Administrative | 4.91M | 942.35K | 1.40M | 623.84K | 429.07K | 402.98K | 390.66K | 331.59K | 174.30K | 6.27K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 4.22K | 33.51K | 14.63K | 19.49K | 80.40K | 3.54 | 0.00 |
| SG&A | 4.91M | 942.35K | 1.40M | 628.06K | 462.58K | 417.61K | 410.16K | 411.99K | 176.70K | 6.27K |
| Other Expenses | 1.46M | 0.00 | 0.00 | 85.24K | 213.13K | 91.36K | 101.14K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 6.47M | 2.93M | 2.55M | 1.87M | 1.25M | 1.26M | 690.69K | 411.99K | 176.70K | 6.27K |
| Cost & Expenses | 6.47M | 5.53M | 2.83M | 2.22M | 1.67M | 1.61M | 791.17K | 411.99K | 176.70K | 6.27K |
| Interest Income | 85.34K | 10.60K | 17.96K | 3.37K | 14.19K | 4.37K | 14.50 | 14.56 | 16.25 | 0.00 |
| Interest Expense | 315.99K | 33.00 | 2.60M | 33.24K | 31.33K | 1.78K | 10.74K | 11.82K | 0.00 | 0.00 |
| Depreciation & Amortization | 225.40K | 564.07K | 126.34K | 106.75K | 94.73K | 51.81K | 33.61K | 11.87K | 169.86K | 0.00 |
| EBITDA | -5.33M | -5.44M | -2.56M | -2.08M | -1.63M | -1.63M | -837.06K | -447.15K | -0.59 | -6.27K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -160.97% | 0.00% |
| Operating Income | -6.47M | 4.00M | -2.70M | -2.15M | -1.68M | -1.62M | -820.98K | -519.90K | -169.86K | -6.27K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -2,481.32% | 0.00% |
| Total Other Income/Expenses | -230.65K | 10.57K | -2.41M | 55.36K | 195.99K | 27.16K | -1.49M | -11.82K | -11.02K | 0.00 |
| Income Before Tax | -6.70M | -3.99M | -5.11M | -2.10M | -1.49M | -1.52M | -2.36M | -519.90K | -180.88K | -6.27K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -2,642.29% | 0.00% |
| Income Tax Expense | 0.00 | 361.20K | 2.41M | 20.51K | -35.00K | -43.75K | 67.10 | 215.78K | -16.25 | 0.00 |
| Net Income | -6.69M | -3.98M | -5.10M | -2.08M | -1.45M | -1.48M | -2.36M | -519.90K | -180.88K | -6.27K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -2,642.29% | 0.00% |
| EPS | -0.01 | 0.00 | -0.01 | -0.01 | 0.00 | 0.00 | -0.01 | 0.00 | -0.01 | 0.00 |
| EPS Diluted | -0.01 | 0.00 | -0.01 | -0.01 | 0.00 | 0.00 | -0.01 | 0.00 | -0.01 | 0.00 |
| Weighted Avg Shares Out | 1.13B | 979.75M | 773.95M | 414.83M | 360.72M | 360.13M | 260.27M | 145.17M | 12.66M | 64.90M |
| Weighted Avg Shares Out (Dil) | 1.13B | 979.75M | 773.95M | 414.83M | 360.72M | 360.13M | 260.27M | 145.17M | 12.66M | 64.90M |
Hemogenyx unveils breakthrough in immune cell technology
Hemogenyx Pharmaceuticals PLC (LSE:HEMO, OTC:HOPHF), the clinical-stage biopharmaceutical company, has announced a significant breakthrough in the delivery of Chimeric Bait Receptors (CBR) to immune cells, marking an important step forward in its development pipeline. This unique approach focuses on enhancing the...
Hemogenyx Pharmaceuticals PLC Announces CBR Macrophage Delivery Update
Breakthrough in Delivering Chimeric Bait Receptors to Immune Cells Accelerates Development LONDON, UK / ACCESSWIRE / December 6, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the clinical-stage biopharmaceutical company, is pleased to announce a breakthrough in its development of a novel...
Clinical trials for HEMO-CAR-T: What's next? ICYMI
Hemogenyx Pharmaceuticals PLC (LSE:HEMO, OTC:HOPHF) CEO Dr.Vladislav Sandler and non-executive director Peter Redmond talked with Proactive about key developments, including its EGM. Redmond explained the reasoning behind share consolidation, aimed at attracting institutional investors and enhancing the company's capital structure as it...
Hemogenyx Pharmaceuticals PLC Announces Notice of Extraordinary General Meeting
Hemogenyx Pharmaceuticals plc ("Hemogenyx Pharmaceuticals" or the "Company") Notice of Extraordinary General Meeting Proposed Capital Reorganisation and New Articles of Association LONDON, UK / ACCESSWIRE / November 22, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group focused on developing...
Hemogenyx Pharmaceuticals gets greenlight for clinical trial
Hemogenyx Pharmaceuticals PLC (LSE:HEMO, OTC:HOPHF) shares drove higher in Friday morning’s dealing, rising over 10% at one point, after it received Institutional Review Board (IRB) approval to begin a Phase I clinical trial for its lead therapy, HEMO-CAR-T, formally designated...
Hemogenyx Pharmaceuticals gets greenlight for clinical trial
Hemogenyx Pharmaceuticals PLC (LSE:HEMO, OTC:HOPHF) told investors it has received Institutional Review Board (IRB) approval to begin a Phase I clinical trial for its lead therapy, HEMO-CAR-T, formally designated HG-CT-1. The trial will target adult patients suffering from relapsed/refractory acute...
Hemogenyx Pharmaceuticals PLC Announces IRB Approval for Phase I Clinical Trial
Hemogenyx Pharmaceuticals Receives IRB Approval for Phase 1 Clinical Trial of HEMO-CAR-T (HG-CT-1) LONDON, UK / ACCESSWIRE / November 22, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), a biopharmaceutical company developing innovative therapies and treatments for blood diseases, is pleased to...
Hemogenyx receives £600,000 institutional boost
Hemogenyx Pharmaceuticals PLC (LSE:HEMO, OTC:HOPHF), the biopharmaceutical company developing treatments for blood diseases, has secured £600,000 in funding from an unnamed institutional investor. The new investment will support the upcoming phase I clinical trials of Hemogenyx's Chimeric Antigen Receptor T-cell therapy,...
Hemogenyx Pharmaceuticals PLC Announces Institutional Investment
Institutional Investment of £600,000 Hemogenyx Pharmaceuticals Secures £0.6m for Phase I Clinical Trials LONDON, UNITED KINGDOM / ACCESSWIRE / November 11, 2024 / Hemogenyx Pharmaceuticals plc ("Hemogenyx Pharmaceuticals" or the "Company")(LSE:HEMO), the biopharmaceutical group focused on developing new therapies for...
Hemogenyx Pharmaceuticals provides timeline for trial of potentially breakthrough leukaemia treatment
Hemogenyx Pharmaceuticals PLC (LSE:HEMO, OTC:HOPHF) has announced the timeline for its upcoming phase I clinical trial of HEMO-CAR-T, a new treatment for adult patients with relapsed or treatment-resistant acute myeloid leukaemia, a severe form of blood cancer. It has finalised all necessary...
Source: https://incomestatements.info
Category: Stock Reports